Premier Functional Medicine
Learn how tesamorelin works, its effects on visceral abdominal fat and body composition, potential benefits, risks and who may be a candidate for treatment.
If you exercise regularly, eat well, and still struggle with fat around your midsection, you may have heard about tesamorelin.
Tesamorelin is a peptide medication that stimulates your body to release more of its own growth hormone. It has received attention because research has demonstrated an ability to reduce visceral abdominal fat in a specific patient population.
But tesamorelin is not simply another weight-loss medication—and it is not appropriate for everyone.
At Premier Functional Medicine in Chandler, Arizona, we believe patients should understand what a therapy does, what the research actually shows, and its potential risks before considering treatment.
What Is Tesamorelin?
Tesamorelin is a synthetic version of growth hormone-releasing hormone (GHRH).
Rather than supplying growth hormone directly, tesamorelin signals the pituitary gland to increase production and release of the body’s own growth hormone. This subsequently increases IGF-1 (insulin-like growth factor-1), which is involved in metabolism, body composition, tissue growth, and recovery.
Tesamorelin is FDA-approved for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It is specifically not FDA-approved as a general weight-loss medication.
Why Is Visceral Fat Important?
Not all body fat is the same.
Subcutaneous fat is the fat located just underneath your skin—the type you can typically pinch.
Visceral fat is located deeper inside the abdomen and surrounds internal organs.
Excess visceral fat has been associated with metabolic problems such as insulin resistance, abnormal cholesterol and triglycerides, cardiovascular risk, and fatty liver disease.
This is one reason visceral fat has become an important area of research in metabolic health.
What Does the Research Show?
Tesamorelin has some of its strongest evidence for reducing visceral abdominal fat in adults with HIV-associated lipodystrophy.
In one major randomized clinical trial, visceral abdominal fat decreased approximately 15% after 26 weeks in participants receiving tesamorelin, while visceral fat increased in the placebo group.
Other clinical research has demonstrated reductions of approximately 10–18% in visceral fat over six to twelve months in this specific population.
Importantly, tesamorelin does not appear to reduce subcutaneous fat to the same degree. This means it should not be viewed as a medication designed simply to make someone lose weight everywhere.
Can Tesamorelin Help With Body Composition?
Potentially—but this needs to be discussed carefully.
Research has shown changes in visceral fat, waist measurements, trunk fat and, in some studies, lean body mass.
This has created interest in tesamorelin outside its FDA-approved indication.
However, evidence supporting tesamorelin for general weight management, anti-aging, athletic performance or routine body-composition enhancement is much more limited than the evidence supporting its approved use in HIV-associated lipodystrophy.
Tesamorelin should not be confused with GLP-1 medications such as semaglutide or tirzepatide. Its mechanism and approved indication are different.
Potential Benefits Being Studied
Depending on the individual and the reason treatment is being considered, areas of interest may include:
These potential benefits should not be interpreted as guaranteed results.
Tesamorelin and Muscle
Growth hormone and IGF-1 are involved in maintaining normal muscle and tissue physiology.
A recent analysis of randomized trials in people with HIV-associated lipodystrophy found that tesamorelin treatment was associated with an increase in lean body mass in addition to reductions in visceral and trunk fat.
That does not mean tesamorelin is an anabolic steroid or that it should be considered a muscle-building drug.
Exercise—particularly resistance training—along with adequate protein, sleep, and appropriate hormone and metabolic health remains fundamental to maintaining muscle.
Is Tesamorelin a Weight-Loss Peptide?
Not in the traditional sense.
The FDA prescribing information specifically states that tesamorelin is not indicated for weight-loss management.
Someone could experience a meaningful change in visceral fat without seeing a dramatic change on the scale.
This is why we prefer to evaluate more than body weight alone. Depending on the patient’s goals, measurements such as waist circumference, laboratory markers and body-composition testing may provide additional useful information.
Are There Risks?
Yes.
Because tesamorelin increases growth hormone and IGF-1 activity, treatment requires appropriate medical evaluation and monitoring.
Potential adverse effects can include:
Tesamorelin can potentially contribute to glucose intolerance, making glucose and A1c monitoring particularly important in patients with metabolic risk factors.
Who Should Not Use Tesamorelin?
Tesamorelin is not appropriate for everyone.
The FDA-approved product is contraindicated in certain situations, including active malignancy, pregnancy, and disruption of the hypothalamic-pituitary axis from conditions such as pituitary surgery, pituitary tumors, head irradiation or significant head trauma.
A history of cancer requires careful individualized evaluation because growth hormone and IGF-1 are involved in cellular growth signaling.
Other medical conditions may also make treatment inappropriate.
What Should Be Checked Before Treatment?
A thoughtful evaluation should come before any peptide prescription.
Depending on your medical history and treatment goals, your provider may evaluate:
These results help determine whether treatment is appropriate and establish a baseline for monitoring.
A Personalized Approach to Body Composition
At Premier Functional Medicine, we don’t believe every patient needs the same medication or peptide.
Persistent abdominal fat or difficulty changing body composition can have multiple contributors, including:
Understanding the underlying issue allows us to develop a more individualized strategy.
Does tesamorelin burn belly fat?
Clinical trials have shown that tesamorelin can reduce visceral abdominal fat in adults with HIV-associated lipodystrophy. It is not FDA-approved as a general belly-fat or weight-loss treatment.
Is tesamorelin the same as a GLP-1?
No. Tesamorelin works through the growth hormone/IGF-1 pathway, while GLP-1 medications primarily affect appetite, glucose regulation and food intake.
Does tesamorelin increase growth hormone?
Yes. Tesamorelin stimulates the pituitary gland to increase the body’s own growth hormone secretion, which subsequently increases IGF-1.
Do you lose weight with tesamorelin?
Tesamorelin can reduce visceral fat without producing a corresponding large reduction in total body weight. It is not FDA-approved for weight-loss management.
Does tesamorelin require blood work?
Medical monitoring is important because tesamorelin can increase IGF-1 and affect glucose metabolism. Appropriate testing depends on the individual patient’s medical history and treatment plan.
